JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

Cancer Clinical Trial

— JUMP  

Official title:

Prevalence of Sarcopenia and Chemobrain in Post-cancer Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05800535
• Other study ID #: 813
• Secondary ID: 69HCL23_0177
• Status: Active, not recruiting
• Start date: March 1, 2023
• Est. completion date: December 31, 2028

Study information

• Verified date: March 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital).

JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers.

This study is non-interventional, it uses research on data that is already collected as part of conventional care, during the JUMP evaluation day.

This study allows the investigators to constitute a cohort of patients to study different parameters related to the disease or to the treatments received.

Our main objective in this study is to describe the muscular and neurocognitive impairment of post-cancer patients evaluated as part of the JUMP program.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

• Age : 18 to 74 years

• localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy

• patient who benefited from the post-cancer assessment day-

Exclusion Criteria:

• Under 18years

• Over 74 years

• Patient who did not received any chemical treatment

• Patient who do not wish to participate

Related Conditions & MeSH terms

• Cancer
• Chemotherapy-Related Cognitive Impairment
• Sarcopenia

Intervention

Drug:
• Study of the adverse effects of long-term oncological treatments
Cognitive and muscular evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Behavioral:
• Study of the long-term side effects of oncological treatments on the anxiety-depressive and cognitive state of patients
Cognitive and anxiety-depressive evaluation of patients who have received oncological treatments, away from the latest treatments to assess their impacts

Locations

Country	Name	City	State
France	Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud	Pierre-Bénite

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of patients with physical and neurocognitive impairment	Number of patients whose medical assessments show altered physical, cognitive or anxiety/dpression activity compared to the measurement in the general population	at least 1 year later after chemical treatments